Genedata Expressionist Boosts Speed and Accuracy of Biotherapeutics Characterization
Genedata adds major new functionality and significantly improves many popular features of the leading software platform for characterization of biopharmaceuticals in drug discovery, development and manufacturing
March 15, 2016
Bethesda, MD, USA
Genedata, a leading provider of advanced software solutions for drug discovery and development, today announced the launch of Release 10.0 of its market-leading mass spectrometry software platform Genedata Expressionist®. The latest version of the software for characterization of biotherapeutics is being demonstrated simultaneously at the 2016 Biotherapeutics Analytical Summit in Bethesda, MD, USA and at CASSS Analytical Technologies Europe 2016 in Vienna, Austria.
Genedata Expressionist has a rapidly growing base of users in major biopharmaceutical R&D organizations, whose continuously evolving requirements have been addressed by adding major new functionality and significantly improving existing features of Genedata Expressionist. Improvements include the refinement and enhancement of peak detection, deconvolution of spectra, and platform scalability.
All-new functionalities of Release 10.0 include:
- Quantification of intact proteins by UV—users are now able to process MS and UV data together for more accurate quantification of proteins;
- High resolution intact protein analysis, enabling greater accuracy in protein identification;
- Manual review of automated annotations, allowing maximum control for validation;
- User interface-based batch processing, saving time by automatically processing thousands of biotherapeutics with changing sequences in one batch;
- Expanded support of peptide fragmentation technologies including ETD and ECD fragmentation;
- A glycan library editor, allowing users to build or modify their own libraries of glycans;
- Vector graphics for the production of visually appealing, compelling reports.
Genedata Expressionist was initially designed over ten years ago as a flexible vendor-independent software platform for proteomics and metabolomics. Since then the software has evolved as a highly scalable system with a special emphasis on harmonizing and automating complex data analysis workflows related to biotherapeutics characterization. The end-to-end enterprise software platform integrates state-of-the-art algorithms, intuitive visualizations, and reporting for quick decision-making, as well as data and method management enabling reproducible, high-quality results with significant time and cost savings.
“I am excited about this major step forward with the latest release of Genedata Expressionist,” said Dr. Othmar Pfannes, CEO of Genedata. “Built on its highly scalable foundation, we have further refined and improved our market-leading software platform, addressing major requirements in the rapidly evolving field of characterization of biopharmaceuticals. We will continue to make significant investments in developing the platform further, based on close collaboration with our leading biopharmaceutical partners, to make it the platform of choice for all characterization work.”
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.